Tytoń i palenie: interakcje

Patients who are current or past smokers are at additional increased risk [see Warnings and Precautions (5.3) ] . (etykieta leku Abrocytynib, Ostrzeżenie w ramce)

Patients who are current or past smokers are at additional increased risk [see Warnings and Precautions ( 5.3 )]. (etykieta leku Baricytynib, Ostrzeżenie w ramce)

WARNING: CARDIOVASCULAR RISK ASSOCIATED WITH SMOKING Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive use. (etykieta leku Dezogestrel + etynyloestradiol, Ostrzeżenie w ramce)

Cigarette smoking increases the risk of serious adverse effects on the heart and blood vessels from oral contraceptive use. (etykieta leku Dioctan etynodiolu + etynyloestradiol, Ostrzeżenie w ramce)

WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptives (COC) use. (etykieta leku Drospirenon + etynyloestradiol, Ostrzeżenie w ramce)

Instruct the patient to avoid heat, flame, and/or smoking during and immediately following application. (etykieta leku Ekonazol, Ostrzeżenia i środki ostrożności)

Avoid smoking tobacco (CYP1A2 inducer) and avoid concomitant use of erlotinib with moderate CYP1A2 inducers (e.g., teriflunomide, rifampin, or phenytoin). (etykieta leku Erlotynib, Interakcje z innymi lekami)

WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptives (COC) use. (etykieta leku Estradiol + dienogest, Ostrzeżenie w ramce)

WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS Cigarette smoking increases the risk of serious cardiovascular events from combination hormonal contraceptive (CHC) use. (etykieta leku Etonogestrel + etynyloestradiol, Ostrzeżenie w ramce)

Therefore, patients being treated with phenelzine sulfate should avoid high protein food that has undergone protein breakdown by aging, fermentation, pickling, smoking, or bacterial contamination. (etykieta leku Fenelzyna, Przeciwwskazania)

Instruct the patient the avoid fire, flame, and smoking during and immediately following application. (etykieta leku Kalcypotriol, Ostrzeżenia i środki ostrożności)

WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS Cigarette smoking increases the risk of serious cardiovascular events from combined hormonal contraceptive (CHC) use. (etykieta leku Lewonorgestrel + etynyloestradiol, Ostrzeżenie w ramce)

Patients with congenital (Leber's) optic atrophy or with tobacco amblyopia have unusually high cyanide/thiocyanate ratios. (etykieta leku Nitroprusydek sodu, Przeciwwskazania)

WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS and CONTRAINDICATED IN WOMEN WITH A BMI |GTE 30 kg/m2 • Cigarette Smoking and Serious Cardiovascular Events Cigarette smoking increases the risk of serious cardiovascular events from hormonal contraceptive use. (etykieta leku Norelgestromin + etynyloestradiol, Ostrzeżenie w ramce)

WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive (COC ) use. (etykieta leku Noretysteron + etynyloestradiol, Ostrzeżenie w ramce)

WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive (COC) use. (etykieta leku Norgestrel + etynyloestradiol, Ostrzeżenie w ramce)

WARNING: CIGARETTE SMOKING and SERIOUS CARDIOVASCULAR EVENTS WARNING: CIGARETTE SMOKING and SERIOUS CARDIOVASCULAR EVENTS See full prescribing information for complete boxed warning. ● Mono-Linyah is contraindicated in women over 35 years old who smoke. (etykieta leku Norgestymat + etynyloestradiol, Ostrzeżenie w ramce)

Patients who are current or past smokers are at additional increased risk. (etykieta leku Tofacytynib, Ostrzeżenie w ramce)

Patients who are current or past smokers are at additional increased risk [see Warnings and Precautions ( 5.3 )] . (etykieta leku Upadacytynib, Ostrzeżenie w ramce)

In a smoking cessation trial in patients with stable CV disease, CV events were infrequent overall; however, nonfatal myocardial infarction (MI) and nonfatal stroke occurred more frequently in patients treated with CHANTIX compared to placebo. (etykieta leku Wareniklina, Ostrzeżenia i środki ostrożności)

As a precaution, the underlying risk of coronary heart disease should be considered when prescribing antiretroviral therapies, including abacavir, and action taken to minimize all modifiable risk factors (e.g., hypertension, hyperlipidemia, diabetes mellitus, smoking). (etykieta leku Abakawir, Ostrzeżenia i środki ostrożności)

As a precaution, the underlying risk of coronary heart disease should be considered when prescribing antiretroviral therapies, including abacavir, and action taken to minimize all modifiable risk factors (e.g., hypertension, hyperlipidemia, diabetes mellitus, smoking). (etykieta leku Abakawir + lamiwudyna, Ostrzeżenia i środki ostrożności)

When receiving intravenous ORENCIA, patients that require blood glucose monitoring should be advised to consider methods that do not react with maltose, such as those based on glucose dehydrogenase nicotine adenine dinucleotide (GDH-NAD), glucose oxidase, or glucose hexokinase test methods. (etykieta leku Abatacept, Interakcje z innymi lekami)

In controlled trials of other TNF blockers in adult patients at higher risk for malignancies (i.e., patients with COPD with a significant smoking history and cyclophosphamide-treated patients with Wegener’s granulomatosis), a greater portion of malignancies occurred in the TNF blocker group compared to the control group. (etykieta leku Adalimumab, Ostrzeżenia i środki ostrożności)

…elevations for longer periods Hypothyroidism Liver disease; cirrhosis, acute hepatitis Reduced renal function in infants <3 months of age Sepsis with multi-organ failure Shock Cessation of Smoking Drug Interactions Adding a drug that inhibits theophylline metabolism (e.g., cimetidine, erythromycin, tacrine) or stopping a concurrently administered drug that enhances theophylline… (etykieta leku Aminofilina, Ostrzeżenia)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, post menopausal status, tobacco use, advance age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (etykieta leku Budezonid, Ostrzeżenia i środki ostrożności)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (etykieta leku Budezonid + formoterol, Ostrzeżenia i środki ostrożności)

Monitoring of blood pressure is recommended in patients who receive the combination of bupropion and nicotine replacement. (etykieta leku Bupropion, Ostrzeżenia i środki ostrożności)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants; or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (etykieta leku Celekoksyb, Ostrzeżenia i środki ostrożności)

Cigarette Smoking (CYP1A2 Inducer) In healthy male heavy smokers, the mean quinine AUC following a single 600 mg dose was 44% lower, the mean C max was 18% lower, and the elimination half-life was shorter (7.5 hours versus 12 hours) than in their non-smoking counterparts. (etykieta leku Chinina, Interakcje z innymi lekami)

In addition, the majority of more recent case-control and cohort studies of benzodiazepine use during pregnancy, which were adjusted for confounding exposures to alcohol, tobacco and other medications, have not confirmed these findings. (etykieta leku Chlordiazepoksyd, Interakcje z innymi lekami)

Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (etykieta leku Diflunisal, Ostrzeżenia)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (etykieta leku Diklofenak, Ostrzeżenia i środki ostrożności)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (etykieta leku Diklofenak + mizoprostol, Ostrzeżenia i środki ostrożności)

Perform a cardiovascular evaluation in triptan-naïve patients who have multiple cardiovascular risk factors (e.g., increased age, diabetes, hypertension, smoking, obesity, strong family history of CAD) prior to receiving RELPAX. (etykieta leku Eletryptan, Ostrzeżenia i środki ostrożności)

Smokers have an increased clearance of benzodiazepines as compared to nonsmokers; this was seen in studies with estazolam (see CLINICAL PHARMACOLOGY ). (etykieta leku Estazolam, Interakcje z innymi lekami)

Risk factors for arterial vascular disease (e.g., hypertension, diabetes mellitus, tobacco use, hypercholesterolemia, and obesity) and/or venous thromboembolism (e.g., personal history or family history of VTE, obesity, and systemic lupus erythematosus) should be managed appropriately. a. (etykieta leku Estradiol, Ostrzeżenia)

Manage appropriately any risk factors for arterial vascular disease (for example, hypertension, diabetes mellitus, tobacco use, hypercholesterolemia, and obesity) and/or venous thromboembolism (VTE) (for example, personal history or family history of VTE, obesity, and systemic lupus erythematosus). (etykieta leku Estradiol + noretysteron, Ostrzeżenia i środki ostrożności)

Risk factors for arterial vascular disease (e.g., hypertension, diabetes mellitus, tobacco use, hypercholesterolemia, and obesity) and/or venous thromboembolism (e.g., personal history or family history of VTE, obesity, and systemic lupus erythematosus) should be managed appropriately. (etykieta leku Estrogeny estryfikowane + metylotestosteron, Ostrzeżenia)

Risk factors for arterial vascular disease (for example, hypertension, diabetes mellitus, tobacco use, hypercholesterolemia, and obesity) and/or venous thromboembolism (VTE) (for example, personal history or family history of VTE, obesity, and systemic lupus erythematosus) should be managed appropriately. a. (etykieta leku Estrogeny skoniugowane, Ostrzeżenia)

Risk factors for arterial vascular disease (for example, hypertension, diabetes mellitus, tobacco use, hypercholesterolemia, and obesity) and/or VTE (for example, personal history or family history of VTE, obesity, and systemic lupus erythematosus) should be managed appropriately. (etykieta leku Estrogeny skoniugowane + bazedoksyfen, Ostrzeżenia i środki ostrożności)

Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (etykieta leku Etodolak, Ostrzeżenia)

Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (etykieta leku Fenoprofen, Ostrzeżenia i środki ostrożności)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking, use of alcohol, older age, and poor general health status. (etykieta leku Flurbiprofen, Ostrzeżenia i środki ostrożności)

In patients susceptible to aniline toxicity (e.g. persons with glucose-6-phosphate dehydrogenase deficiency, hemoglobin M disease and smokers), monitoring of methemoglobin levels should be considered. (etykieta leku Flutamid, Ostrzeżenia)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids), should be monitored and treated with established standards of care. (etykieta leku Flutykazon, Ostrzeżenia i środki ostrożności)

Theophylline: The effect of steady-state fluvoxamine (50 mg bid) on the pharmacokinetics of a single dose of theophylline (375 mg as 442 mg aminophylline) was evaluated in 12 healthy non-smoking, male volunteers. (etykieta leku Fluwoksamina, Ostrzeżenia i środki ostrożności)

Perform a cardiovascular evaluation in triptan-naïve patients who have multiple cardiovascular risk factors (e.g., increased age, diabetes, hypertension, smoking, obesity, strong family history of CAD) prior to receiving frovatriptan succinate. (etykieta leku Frowatryptan, Ostrzeżenia i środki ostrożności)

Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (etykieta leku Hydrokodon + ibuprofen, Ostrzeżenia)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (etykieta leku Ibuprofen, Ostrzeżenia i środki ostrożności)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (etykieta leku Ibuprofen + famotydyna, Ostrzeżenia i środki ostrożności)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (etykieta leku Indometacyna, Ostrzeżenia i środki ostrożności)

In both cases, a prior history of heavy tobacco use was identified as a risk factor for lung cancer. (etykieta leku Insulina ludzka krótko działająca, Ostrzeżenia i środki ostrożności)

Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (etykieta leku Ketoprofen, Ostrzeżenia)

In addition to past history of ulcer disease, other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids, or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (etykieta leku Ketorolak, Ostrzeżenia i środki ostrożności)

In addition, the majority of more recent case-control and cohort studies of benzodiazepine use during pregnancy, which were adjusted for confounding exposures to alcohol, tobacco and other medications, have not confirmed these findings. (etykieta leku Klorazepan, Interakcje z innymi lekami)

• Discontinuation of CYP1A2 or CYP3A4 Inducers: Consider reducing CLOZARIL dose when CYP1A2 inducers (e.g., tobacco smoke) or CYP3A4 inducers (e.g., carbamazepine) are discontinued. (etykieta leku Klozapina, Interakcje z innymi lekami)

Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy, concomitant use of oral corticosteroids, anti-platelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs), smoking, use of alcohol, older age, and poor general health status. (etykieta leku Kwas mefenamowy, Ostrzeżenia i środki ostrożności)

Patients with known risk factors, including prior thrombosis, may be at greater risk and actions should be taken to try to minimize all modifiable factors (e.g. hyperlipidemia, hypertension, smoking). (etykieta leku Lenalidomid, Ostrzeżenia i środki ostrożności)

MPA Injectable Suspension, USP can pose an additional risk in patients with risk factors for osteoporosis (e.g., metabolic bone disease, chronic alcohol and/or tobacco use, anorexia nervosa, strong family history of osteoporosis or chronic use of drugs that can reduce bone mass such as anticonvulsants or corticosteroids). (etykieta leku Medroksyprogesteron, Ostrzeżenia i środki ostrożności)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (etykieta leku Meloksykam, Ostrzeżenia i środki ostrożności)

Coronary artery disease Patients with coronary artery disease or risk factors for coronary artery disease (e.g., smoking, obesity, diabetes, high cholesterol) may be more susceptible to developing myocardial ischemia and infarction associated with methylergonovine-induced vasospasm. (etykieta leku Metyloergometryna, Ostrzeżenia)

Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (etykieta leku Nabumeton, Ostrzeżenia)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (etykieta leku Naproksen, Ostrzeżenia i środki ostrożności)

Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (etykieta leku Naproksen + ezomeprazol, Ostrzeżenia i środki ostrożności)

Perform a cardiovascular evaluation in triptan-naive patients who have multiple cardiovascular risk factors (e.g., increased age, diabetes, hypertension, smoking, obesity, strong family history of CAD) prior to receiving naratriptan tablets. (etykieta leku Naratryptan, Ostrzeżenia i środki ostrożności)

WARNINGS Cigarette smoking increases the risk of serious cardiovascular disease. (etykieta leku Noretysteron, Ostrzeżenia)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (etykieta leku Oksaprozyna, Ostrzeżenia i środki ostrożności)

This results in a mean increase in olanzapine Cmax following fluvoxamine of 54% in female nonsmokers and 77% in male smokers. (etykieta leku Olanzapina, Interakcje z innymi lekami)

This results in a mean increase in olanzapine C max following fluvoxamine administration of 54% in female nonsmokers and 77% in male smokers. (etykieta leku Olanzapina + fluoksetyna, Interakcje z innymi lekami)

The impact of longer exposure to omalizumab products or use in patients at higher risk for malignancy (e.g., elderly, current smokers) is not known. (etykieta leku Omalizumab, Ostrzeżenia i środki ostrożności)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy, concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (etykieta leku Paracetamol + ibuprofen, Ostrzeżenia i środki ostrożności)

Tobacco Smoking tobacco could enhance the metabolic clearance rate of pentazocine reducing the clinical effectiveness of a standard dose of pentazocine. (etykieta leku Pentazocyna + nalokson, Interakcje z innymi lekami)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (etykieta leku Piroksykam, Ostrzeżenia i środki ostrożności)

Patients with known risk factors, including prior thrombosis, may be at greater risk, and actions should be taken to try to minimize all modifiable factors (e.g., hyperlipidemia, hypertension, smoking). (etykieta leku Pomalidomid, Ostrzeżenia i środki ostrożności)

Drugs that inhibit these CYP pathways (such as desipramine, paroxetine, ritonavir, sertraline for CYP2D6; ketoconazole, erythromycin, saquinavir, and grapefruit juice for CYP3A4; and amiodarone and tobacco smoke for CYP1A2) can be expected to cause increased plasma levels of propafenone. (etykieta leku Propafenon, Ostrzeżenia i środki ostrożności)

CYP1A2 and CYP2C19 Inducers: CYP1A2 inducers (e.g., phenytoin, montelukast, smoking) and CYP2C19 inducers (e.g. rifampin) decrease the plasma levels of propranolol resulting in a loss of efficacy [see Clinical Pharmacology ( 12.7 )] . (etykieta leku Propranolol, Interakcje z innymi lekami)

The risk-benefit balance should be considered in women at risk for stroke, such as prior stroke or transient ischemic attack (TIA), atrial fibrillation, hypertension, or cigarette smoking [see Clinical Studies ( 14.5 )] . (etykieta leku Raloksyfen, Ostrzeżenia i środki ostrożności)

Pharmacokinetic Interactions with Adempas Smoking: Plasma concentrations in smokers are reduced by 50% to 60% compared to nonsmokers. (etykieta leku Riocyguat, Interakcje z innymi lekami)

Cigarette smoking is expected to increase the clearance of ropinirole since CYP1A2 is known to be induced by smoking hormone replacement therapy [ see Clinical Pharmacology ( 12.3 ) ]. (etykieta leku Ropinirol, Interakcje z innymi lekami)

Secondary Malignancies: Monitor for development of secondary malignancies, particularly in patients who are current or past smokers. (etykieta leku Ruksolitynib, Ostrzeżenia i środki ostrożności)

In this study, current or past smokers had an additional increased risk of overall malignancies. (etykieta leku Rytlecytynib, Ostrzeżenia i środki ostrożności)

Triptan-naïve patients who have multiple cardiovascular risk factors (e.g., increased age, diabetes, hypertension, smoking, obesity, strong family history of CAD) should have a cardiovascular evaluation prior to receiving MAXALT. (etykieta leku Ryzatryptan, Ostrzeżenia i środki ostrożności)

Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (etykieta leku Salsalat, Ostrzeżenia)

Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (etykieta leku Sulindak, Ostrzeżenia)

Perform a cardiovascular evaluation in triptan-naive patients who have multiple cardiovascular risk factors (e.g., increased age, diabetes, hypertension, smoking, obesity, strong family history of CAD) prior to receiving IMITREX tablets. (etykieta leku Sumatryptan, Ostrzeżenia i środki ostrożności)

Perform a cardiovascular evaluation in patients who have multiple cardiovascular risk factors (e.g., increased age, diabetes, hypertension, smoking, obesity, strong family history of CAD) prior to receiving sumatriptan and naproxen sodium tablets. (etykieta leku Sumatryptan + naproksen, Ostrzeżenia i środki ostrożności)

Cessation of Smoking: Drug Interactions: Adding a drug that inhibits theophylline metabolism (e.g., cimetidine, erythromycin, tacrine) or stopping a concurrently administered drug that enhances theophylline metabolism (e.g., carbamazepine, rifampin). (etykieta leku Teofilina, Ostrzeżenia)

Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (etykieta leku Tolmetyna, Ostrzeżenia)

…contraceptives, phenylpropanolamine, propafenone, propranolol, terbinafine, thiabendazole, ticlopidine, verapamil, zileuton montelukast, moricizine, omeprazole, phenobarbital, phenytoin, cigarette smoking CYP3A4 alprazolam, amiodarone, amlodipine, amprenavir, aprepitant, atorvastatin, atazanavir, bicalutamide, cilostazol, cimetidine, ciprofloxacin, clarithromycin, conivaptan,… (etykieta leku Warfaryna, Interakcje z innymi lekami)

Perform a cardiovascular evaluation in triptan-naïve patients who have multiple cardiovascular risk factors (e.g., increased age, diabetes, hypertension, smoking, obesity, strong family history of CAD) prior to receiving zolmitriptan. (etykieta leku Zolmitryptan, Ostrzeżenia i środki ostrożności)

Quinidine's pharmacokinetics are also unaffected by cigarette smoking. (etykieta leku Chinidyna, Interakcje z innymi lekami)

Tobacco and other medications, have not confirmed these findings. (etykieta leku Chlordiazepoksyd + klidynium, Interakcje z innymi lekami)

Ask a doctor before use if you have chronic cough that lasts such as occurs with smoking, asthma, or emphysema cough that occurs with too much phlegm (mucus) Stop use and ask a doctor if cough lasts more than 7 days, comes back, or occurs with fever, rash, or headache that lasts. (etykieta leku Dekstrometorfan, Ostrzeżenia)

Nicotine Nicotine may provoke vasoconstriction in some patients, predisposing to a greater ischemic response to ergot therapy. (etykieta leku Dihydroergotamina, Interakcje z innymi lekami)

Nicotine may provoke vasoconstriction in some patients, predisposing to a greater ischemic response to ergot therapy. (etykieta leku Ergotamina + kofeina, Interakcje z innymi lekami)

Other Interactions Digitalis, tetracyclines, nicotine, or antihistamines, or intravenous nitroglycerin may partially counteract the anticoagulant action of heparin sodium. (etykieta leku Heparyna, Interakcje z innymi lekami)

All patients had a history of heavy smoking [see Adverse Reactions (6.1) ] . (etykieta leku Infliksymab, Ostrzeżenia i środki ostrożności)

This is of particular concern in women who are obese or smoke cigarettes, especially smokers over 35 years of age. (etykieta leku Kwas traneksamowy, Ostrzeżenia i środki ostrożności)

Some patients who stopped smoking may have been experiencing symptoms of nicotine withdrawal, including depressed mood. (etykieta leku Naltrekson + bupropion, Ostrzeżenia i środki ostrożności)